- HIV infection:
- 1 tab BD
Tablet: 150mg/300mg
None remarkable
Lamivudine: NRTI; Following phosphorylation, it inhibits HIV reverse transcriptase by viral DNA chain termination
Zidovudine: NRTI; It interferes with HIV viral RNA-dependent DNA polymerase inhibiting viral replication
- Headache
- Nausea
- Vomiting
- Malaise
- Fatigue
- Cough
- Diarrhea
- Neuropathy
- Musculoskeletal pain
- Insomnia
- Dizziness
- Fever
- Rigors
- Anorexia
- Abdominal cramps
- Abdominal pain
- Depression
- Rash
- Arthralgia
- Myalgia
- Neutropenia
- Dyspepsia
- Hyperamylasemia
- Elevated LFTs
- Anemia
- Asthenia
- Constipation
- Hepatomegaly
- Stomatitis
- Lipoatrophy
- Hypersensitivity
- Patients requiring separate lamivudine or zidovudine dose reduction
WARNING:
- Risk of zidovudine-associated neutropenia and severe anemia, especially in patients with advanced HIV
- Symptomatic myopathy associated with prolonged zidovudine use
- Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, associated with nucleoside analogue use and other antiretrovirals
- Increased risk if female, obese, or long-term nucleoside analogue treatment
- Severe acute HBV exacerbations in HBV or HBV/HIV co-infected patients upon lamivudine discontinuation
- Elvitegravir/cobicistat/emtricitabine/tenofovir DF
- Emtricitabine
Drug Status
| Availability | Prescription only |
| Pregnancy | Category C |
| Breastfeeding | Contraindicated |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Combivir | 150mg/300mg | Tablet | 60’s | GSK Ltd | GSK Ltd |
| Duovir | 150mg/300mg | Tablet | 60’s | Cipla | Phillips Therapeutics |
| Lamivudine/Zidovudine | 150mg/300mg | Tablet | 60’s | Mylan Labs C/O Surgilinks Ltd | Surgilinks Ltd |
| Lamozid | 150mg/300mg | Tablet | 60’s | Universal Corporation | Universal Corporation |
| Lazidariv | 150mg/300mg | Tablet | 60’s | Cosmos Ltd | Cosmos Ltd |
| Zidolam | 150mg/300mg | Tablet | 60’s | Hetero Labs | Unisel Ltd |